Relmada Therapeutics, Inc.
RLMD
$4.80
$0.051.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.60% | 81.48% | 51.82% | -46.95% | -8.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.86% | 6.82% | -8.61% | -55.12% | -45.69% |
| Operating Income | -46.86% | -6.82% | 8.61% | 55.12% | 45.69% |
| Income Before Tax | -30.89% | -8.50% | -6.49% | 53.55% | 44.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.89% | -8.50% | -6.49% | 53.55% | 44.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.89% | -8.50% | -6.49% | 53.55% | 44.47% |
| EBIT | -46.86% | -6.82% | 8.61% | 55.12% | 45.69% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 61.35% | 61.90% | 47.40% | 57.78% | 49.52% |
| Normalized Basic EPS | 62.07% | 63.46% | 54.30% | 58.63% | 49.59% |
| EPS Diluted | 61.35% | 61.90% | 47.40% | 57.78% | 49.52% |
| Normalized Diluted EPS | 62.07% | 63.46% | 54.30% | 58.63% | 49.59% |
| Average Basic Shares Outstanding | 238.57% | 184.77% | 102.48% | 10.00% | 10.00% |
| Average Diluted Shares Outstanding | 238.57% | 184.77% | 102.48% | 10.00% | 10.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |